Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes | |
Goss, G. D.; Felip, E.; Cobo, M.; Lu, S.; Syrigos, K.; Li, K. W.; Zhou, C.; Park, K.; Solca, F.; Kraemer, N. | |
刊名 | EUROPEAN JOURNAL OF CANCER |
2015 | |
卷号 | 51 |
ISSN号 | 0959-8049 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3542284 |
专题 | 吉林大学白求恩第一医院 |
推荐引用方式 GB/T 7714 | Goss, G. D.,Felip, E.,Cobo, M.,et al. Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes[J]. EUROPEAN JOURNAL OF CANCER,2015,51. |
APA | Goss, G. D..,Felip, E..,Cobo, M..,Lu, S..,Syrigos, K..,...&Soria, J. C..(2015).Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes.EUROPEAN JOURNAL OF CANCER,51. |
MLA | Goss, G. D.,et al."Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes".EUROPEAN JOURNAL OF CANCER 51(2015). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论